ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / SNWV
SRTS (41) DAVI (47) MDAI (16) XTNT (65) ⌘ Pro Terminal →

SANUWAVE Health Inc. (SNWV) — RQD Stock Rating Cockpit

$5.15 -2.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.12

SANUWAVE Health Inc. (SNWV) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →
ROARABLE D • SELL / AVOID Cap $44.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SNWV Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SNWV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, SANUWAVE Health Inc. (NASDAQ: SNWV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $5.15 (-2.28% 1D, market cap $44.3M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, SNWV ranks #256 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SNWV compare to SRTS and DAVI in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), SNWV carries a Roarable D (51/100 RQD), trailing P/E of 3.8x, gross margin of 77.1%, and ROIC of 67.3%. By comparison, SRTS (Sensus Healthcare Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -31.3%, cap $45.4M) and DAVI (Davion Healthcare Plc) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $42.0M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SNWV?
▼

Per SNWV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001417663), SANUWAVE Health Inc. generated $44.1M in revenue (+36.3% YoY), $11.8M in net income, and $1.9M in free cash flow against $37.3M in total assets and $16.1M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.12 (-0.60%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 4.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk D-
Cash (11)Whales (7)SEC (10)Macro (5)CEO (18)
Each axis scored 0–20
12M PRICE TARGET CONE-3.1% Base Target
$38 Bull$5 Base$4 Bear
📬 FREE SNWV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNWV)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY SNWV SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (35% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+11/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 4.4% FCF Margin ($1.9M FCF) & 77.1% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (50.1) create a -15 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
59
Grade C$5.61-6.1% Next Q
Q2 (-2Q)
56
Grade C$5.27-2.7% Next Q
Q3 (-1Q)
54
Grade C-$5.13+0.4% Next Q
Current
51
Grade D$5.15-1.3% Hist 90D α
Trajectory: C (59) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SNWV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SNWV currently carries a cautious 51/100 (D) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Company leadership has skin in the game with net positive insider conviction.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.84) and Max Pain ($5.41) forces dealer call-delta covering toward $38.01.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-2.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNWV• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SNWV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
50.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE4% OF RANGE
L: $4$5.15H: $36
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (77% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: D+RQD 11 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 25 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on SNWV

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (55)

67.3% ROIC with 77.1% gross margin and 4.27% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (50)

25/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like SNWV
  • ✓Company leadership has skin in the game with net positive insider conviction.
Bear Case: What Could Go Wrong
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNWV)

  • ✓Walkthrough of SNWV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SNWV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -67.07%▲ RESISTANCE BREAKOUT
2026-11-03O $5.27H $5.27L $5.15C $5.15VOL 11.9K
RES: $4.20SUP: $1.91SMA50: $4.84SMA200: $13.27
$31.43$23.97$16.52$9.06$1.61RES $4.20SUP $1.91$5.152026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNWV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNWV Butterfly Map → + Track SNWV →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
-15.0%/yr Implied 5Y Growth

vs. +36.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SNWV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNWV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SNWV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNWV)

Health Care Rank #256 of 1016 ⚔️ SRTS vs SNWV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNWV vs. SRTS, DAVI, MDAI, XTNT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SANUWAVE Health Inc. (SNWV) ranks #256 by composite RQD confidence (51/100, grade D) and #764 by equity capitalization ($44.3M). Within this direct 5-issuer industry benchmark cohort, SNWV leads on earnings valuation at 3.8x trailing P/E, while SNWV leads on capital efficiency and profitability with 67.3% ROIC and 77.1% gross margin. XTNT currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with SNWV at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SNWV ACTIVE
SANUWAVE Health Inc.
D 51/100 3.8x 77.1% 67.3% -2.28% $44.3M Benchmark Subject
SRTS
Sensus Healthcare Inc.
D- 41/100 — 43.2% -31.3% -0.36% $45.4M /srts-vs-snwv →
DAVI
Davion Healthcare Plc
D 47/100 — — — -37.55% $42.0M /davi-vs-snwv →
MDAI
Spectral AI Inc. (Class A)
E 16/100 — 45.4% -35.0% -2.55% $49.2M /mdai-vs-snwv →
XTNT
Xtant Medical Holdings Inc.
C 65/100 — 62.9% 12.8% -3.51% $39.3M /xtnt-vs-snwv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001417663

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SANUWAVE Health Inc. (SNWV) reported GAAP revenue of $44.1M (+36.3% vs. FY2024 revenue of $32.3M , and +128.8% cumulative change since FY2023) , GAAP net income of $11.8M, operating cash flow of $3.9M, and free cash flow of $1.9M (-1.6% YoY). On the balance sheet, SNWV closed FY2025 with $37.3M in total assets against $16.1M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $44.1M $11.8M $3.9M $1.9M $37.3M $16.1M
FY2024 (FY) 2024-12-31 $32.3M -$33.1M $2.5M $2.0M $30.1M —
FY2023 (FY) 2023-12-31 $19.3M -$25.8M -$4.5M -$4.5M — —

3. SNWV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNWV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, SANUWAVE Health Inc. (NASDAQ: SNWV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $5.15 (-2.28% 1D, market cap $44.3M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, SNWV ranks #256 in composite RQD confidence.

How does SNWV compare to SRTS and DAVI in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SNWV carries a Roarable D (51/100 RQD), trailing P/E of 3.8x, gross margin of 77.1%, and ROIC of 67.3%. By comparison, SRTS (Sensus Healthcare Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -31.3%, cap $45.4M) and DAVI (Davion Healthcare Plc) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $42.0M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SNWV?

Per SNWV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001417663), SANUWAVE Health Inc. generated $44.1M in revenue (+36.3% YoY), $11.8M in net income, and $1.9M in free cash flow against $37.3M in total assets and $16.1M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SNWV trading relative to its 50-day, 200-day, and 52-week technical levels?

SNWV last traded at $5.15 (-2.28% on volume of 11,909 shares), positioning the stock +6.40% above its 50-day simple moving average ($4.84) and -61.19% below its 200-day simple moving average ($13.27). Across its 52-week range of $3.92 to $36.20, SNWV sits at the 3.8% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.51 to $5.79).

SNWV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell SNWV stock right now?

SANUWAVE Health Inc. (SNWV) currently earns a Roarable Rating of D (Sell — SELL) with 51/100 RQD Confidence. Stretched risk/reward at 4x P/E (67% return on capital) under elevated 10-year interest-rate pressure.

What is SNWV's 12-month price target and RQD AI Jury consensus?

SNWV's 12-month base price target is $4.99 (range $3.89 to $38.01), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: SNWV RQD Cockpit SNWV 12M Forecast SNWV Earnings & Move SNWV Dividends & DRIP SNWV Insiders & 13F SNWV Whale Options SNWV Profit Sankey SNWV News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SNWV — SANUWAVE Health Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:47:18Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SNWV scores 52 out of 100 (letter grade D+, verdict "Roarable Sell — Weak Fundamentals / Trim"). The five pillars are: Fundamental Cash Engine 11/20 (ROIC 67.3%; FCF yield 4.27%); Whale/13F Flow 7/20 (institutional accumulation and options positioning); Insider Conviction 18/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 6/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 7/9; Debt/Equity 8.5).

The strongest pillar is insider conviction, which is a potential upside driver if it reflects sustained buying. The weakest are macro regime fit and whale/13F flow, which indicate limited institutional support and sector-level sensitivity. The fundamental cash engine and balance sheet pillars sit in the middle, suggesting that the headline ROIC is not fully corroborated by free cash flow or leverage metrics. For a prospective investor, the valuation tradeoff is that very low reported P/E ratios (3.8 TTM, 3.5 forward) coexist with a weak composite rating, so the discount may reflect durability concerns rather than mispricing. The verdict label itself advises trimming, which implies the rating system does not view current conditions as a favorable entry point.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$5.27$45.3M3.83.57.51.370%1.0$3.92 - $36.267.3%

Business

SANUWAVE Health Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Per the profile, the company is classified in this sector and industry, with a reported market capitalization shown as $0.0B in the profile field and $45.3M in market data. Not available in source data: a detailed description of specific products, customers, or revenue model.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$44.1M$4.9M$11.8MN/A$1.9M$12.0M$16.1M
FY 2024$32.3M$3.8M$-33.1MN/A$2.0M$10.2MN/A
FY 2023$19.3M$-0.5M$-25.8MN/A$-4.5MN/AN/A

Per the SEC financials, revenue grew from $19.3M (FY 2023) to $44.1M (FY 2025), and FY 2025 net income of $11.8M contrasts with prior-year losses. Per the market data, gross margin is 77.1%, operating margin 11.2%, net margin 26.8%, and ROIC 67.3%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 7/9, and Debt/Equity is 8.5. Balance sheet posture shows reported cash of $12.0M against debt of $16.1M for FY 2025.

Recent Catalysts & News Wire Analysis

Per the news wire, recent items include a Q3'26 earnings preview citing a revenue estimate of 13.75M USD (TradingView); a report that the company amended its credit agreement and received a lender waiver on a coverage ratio (Investing.com Nigeria); and a headline on SANUWAVE amending its credit agreement and waiving a coverage-ratio default for a $5,000 fee (TradingView). Other items are general market roundups (Yahoo Finance Australia, TradingKey). All news items carry a YELLOW light and MARKET WIRE impact label. Risk watch: the covenant waiver and coverage-ratio default are the most material items. The butterfly supply-chain graph reports no proprietary signals.

Open Questions

  • What were the specific coverage-ratio terms in the credit agreement, and what covenant headroom remains after the waiver?
  • Why did net income swing from -$33.1M (FY 2024) to +$11.8M (FY 2025), and is that driven by recurring operations or one-time items?
  • What explains the gap between reported ROIC of 67.3% and the FCF of $1.9M in FY 2025?
  • What is the source of the 52-week range spread of $3.92 to $36.2, and what drove the decline?
  • Who are the institutional holders and insiders behind the pillar scores, given that holder data is absent?

SNWV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SANUWAVE Health Inc. (SNWV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SNWV Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SNWV Bull vs. Bear Conversation Board — What's Your Call at $5.15?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SNWV 🐻 50% BEARISH CONVICTION
1. Pick Your Side on SNWV:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $5.69 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SNWV (D+ • RQD 52/100) a Buy at $5.27?

Welcome to the SNWV (SANUWAVE Health Inc.) Roar Pit. Current RQD Composite is 52/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Dental Instruments. Bulls point to capital efficiency (67.3% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.01 (-23.9%)
Spot @ $5.27

Pump the brakes on SNWV — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SNWV, but look at what you are paying: 3.8x trailing P/E with 77.1% gross margins. Unless SANUWAVE Health Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.69 (+26.9%)
Spot @ $5.27

SNWV cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SNWV, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $5.27 (52-wk range $3.92 - $36.20), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%